

RESEARCH ARTICLE

## Highlight on Multidrug Resistance of *Enterococcus faecalis* Recovered from Diabetic Foot Patients

Ahmad ALbeloushi<sup>1,2\*</sup>, Ayman Elbehiry<sup>3,4</sup>, Eman Marzouk<sup>5</sup>, Rasha Zahran<sup>3</sup> and Husam Edrees<sup>4</sup>

<sup>1</sup>Al Bukayriyah General Hospital, Qassim, Kingdom of Saudi Arabia. <sup>2</sup>Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia. <sup>3</sup>Department of Bacteriology, Mycology and Immunology, Faculty of Veterinary Medicine, University of Sadat City, Sadat, Egypt. <sup>4</sup>Department of Public Health, College of Public Health and Health Informatics, Qassim University, Buraidah, Saudi Arabia. <sup>5</sup>Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Saudi Arabia.

### Abstract

Diabetic foot infections (DFIs) are a progressively serious health problem worldwide. *Enterococcus faecalis* (*E. faecalis*) is one of the most frequent bacteria in DFIs. The antibiotic resistance patterns of this bacterium remain a significant tool for monitoring infection. Therefore, our study aimed to determine the susceptibility of *E. faecalis* recovered from the wounds of hospitalized diabetic foot patients to various antimicrobial drugs. Fifty-two *E. faecalis* strains were recovered from 630 diabetic foot patients. All isolates were identified biochemically by a Vitek® 2 system and via a mass spectrometer (MALDI Biotyper). Antimicrobial sensitivity testing used Vitek 2 cards and Kirby-Bauer as the reference method. The findings indicated that the susceptibility of *E. faecalis* was 100% for ampicillin, ampicillin-sulbactam, benzylpenicillin, norfloxacin, and ofloxacin; 92% for nitrofurantoin, teicoplanin, and vancomycin; 87% for imipenem; 81% for kanamycin (high concentration) and tetracycline; 73% for levofloxacin; and 52% for streptomycin (high concentrations). The resistance was 100% for clindamycin and quinupristin-dalfopristin, 96% for cefuroxime, 90% for ciprofloxacin and erythromycin, 86% for trimethoprim-sulfamethoxazole, 54% for gentamicin (high concentration), and 48% for streptomycin (high concentration). All *E. faecalis* strains were resistant against numerous antibiotics with a multiple antibiotic resistance (MAR) index of 0.20–0.60. The mean value of MAR indices for all tested *E. faecalis* species was 0.373. The high levels of antimicrobial resistance patterns to *E. faecalis* seen here are important because they restrict treatment possibilities and adversely affect the health of diabetic foot patients. Consequently, our findings should be carefully considered in public health and awareness programs.

**Keywords:** Diabetic foot infections; *Enterococcus faecalis*; Antibiotic resistance.

\*Correspondence: aalbeloushi@yahoo.com; 00966503140996

(Received: 06 November 2018; accepted: 09 December 2018)

**Citation:** Ahmad ALbeloushi, Ayman Elbehiry, Eman Marzouk, Rasha Zahran and Husam Edrees, Highlight on Multidrug Resistance of *Enterococcus faecalis* Recovered from Diabetic Foot Patients, *J Pure Appl Microbiol.*, 2019; **13**(1):481-489 doi: 10.22207/JPAM.13.1.54

© The Author(s) 2019. **Open Access.** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

## INTRODUCTION

Diabetic foot (DF) is a chronic form of diabetes mellitus (DM) associated with high economic and social problems worldwide<sup>1,2</sup>. Approximately 15% of all diabetic patients eventually have a foot ulcer that is highly susceptible to bacterial infections<sup>3</sup>. Diabetic foot infections (DFIs) are particularly concerning due to the emergence of antibiotic-resistant bacteria<sup>4</sup>. There is currently a shortage of data on casualties of DF—particularly in the Middle East.

Saudi Arabia is a top ten Middle Eastern/Arab countries in terms of diabetes prevalence in adults. This leads to high rates of foot ulcers along with increasing morbidity and costs<sup>5</sup>. Foot ulcers in diabetic patients are more susceptible to various microbial contaminations. These can spread rapidly and often lead to permanent tissue damage. Several bacteria can cause DFIs: Non-spore forming Gram-positive cocci (e.g., Enterococci) are the most common bacteria<sup>2,6</sup>.

Previous studies have shown that the *Enterococcus* genus is a main cause of the increase in the rate of morbidity and mortality in DFIs<sup>7</sup>. This genus is composed of 38 species; *Enterococcus faecalis* (*E. faecalis*) is particularly common and often implicated in the transfer of antimicrobial resistance<sup>8,9</sup>. The clinical significance of *E. faecalis* is often associated with its antimicrobial resistance—this leads to problems with colonization and infection<sup>10</sup>.

One of the biggest problems facing diabetic foot patients is the isolation of a large number of microbes that are resistant to various antibiotics—especially vancomycin-resistant *Enterococci* and methicillin-resistant *Staphylococcus aureus*<sup>2</sup>. The increased frequency of *Enterococcus* in DFIs is a main cause of hospitalization in Saudi hospitals perhaps because of increased antibiotic use. The presence of antibiotic-resistant bacteria highlights the importance of antimicrobial vulnerability testing for diabetic foot patients and the need to avoid excessive use of antimicrobials<sup>4,11</sup>.

Recently, VITEK 2 cards have been approved by the Food and Drug Administration (FDA) for antimicrobial susceptibility testing. This approach is fast, automatic, sensitive, and highly specific<sup>12</sup>. Therefore, the suitable management of *E. faecalis* infections can lead to proper antibiotic choice based on susceptibility test reports<sup>11</sup>.

Primary management includes empirical antibiotic treatment based on local epidemiological data on antimicrobial susceptibility. Information on the microorganisms underlying the infections is critical to determining the appropriate antibiotic therapy<sup>3</sup>. Therefore, this study examined the antimicrobial susceptibility and resistance patterns of *E. faecalis* isolated from ulcers of diabetic foot patients in two hospitals in central Saudi Arabia.

## MATERIALS AND METHODS

### Bacterial strains

We used 52 *E. faecalis* strains recovered from 630 samples collected from diabetic foot patients in the Bukyriah General Hospital (BGH), Al-Qassim region and King Saud Medical City Riyadh from June 2016 to January 2017.

### Identification of *E. faecalis*

The Vitek<sup>®</sup> 2 system (Biom'rieux, France) measured the biochemical profiles of *E. faecalis* isolates based on the manufacturer's instructions. American Type Culture Collection (ATCC) 19433 *E. faecalis* was used as the quality control. The Microflex LT (Bruker Daltonik, Bremen, Germany) was then applied for accurate identification of *E. faecalis* isolates. All procedures and data analysis were performed according to the recommendations provided by Bruker Daltonics Corporation. *Escherichia coli* was used as bacterial test standard (positive control). Genetic analysis detected the presence of *E. faecalis* virulence genes specific to *E. faecalis*. First, genomic DNA extraction was achieved by QuickGene-810 (Fujifilm, Tokyo, Japan). Second, six primer sets specific for *E. faecalis* including *asa1*, *GeIE*, *cylA*, *esp*, *hy1*, *VanA* and *VanB* were amplified using the SYBER Green RT-PCR (Applied Biosystems, USA).

### Antibiotic susceptibility and MAR index of *E. faecalis* using Vitek 2 cards

We used the VITEK 2 AST-P516 cards (BioM'rieux) to detect the susceptibility percentage of *E. faecalis* against various antimicrobial drugs. Each card consists of 64 holes containing 20 antibiotics at different concentrations (Table 1). In brief, 2-3 distinct colonies were suspended in sterilized physiological saline and thoroughly mixed. The McFarland turbidity was adjusted from 0.52 and 0.65 by DensiChek<sup>TM</sup> (BioMe2 rieux, France). Of this suspension, 5 ml was loaded onto the AST-P516 cards. The filled cassette was placed in

the device, and the results were interpreted by the AST-P516 database after an incubation period of 4 h. Likewise, the multiple antibiotic resistance (MAR) index of each isolate was recorded through the calculation designated as follows:

$$\text{MAR index} = \frac{\text{Number of antimicrobial agents to which the bacterium is resistant}}{\text{Total number of antimicrobial agents used in the study}}$$

### Kirby-Bauer as a reference method

The susceptibility of *E. faecalis* to various antibiotics was measured via the Kirby-Bauer method according to Clinical and Laboratory Standards Institute guidelines<sup>13</sup>. The results were sensitive, intermediate, or resistant according to

the diameter of the inhibitory zones using CLSI breakpoints. The concentration ranges ( $\mu\text{g/ml}$ ) of the antimicrobial agents and breakpoints used in antibiotic susceptibility test were demonstrated in Table 1. *E. faecalis* ATCC 29212 was used as a quality control bacterium for all tests<sup>14</sup>.

## RESULTS

### Frequency and identification of *E. faecalis*

The occurrence of *E. faecalis* was studied in 630 patients suffering from diabetic foot ulcers. Our findings revealed that 74 samples were positive to various types of bacteria including fifty two *E. faecalis*, eight *Acinetobacterbaumanni*,

**Table 1.** Concentration range ( $\mu\text{g/ml}$ ) of antimicrobial agents and breakpoints used in antibiotic susceptibility test

Antimicrobial agent	MIC ( $\mu\text{g/ml}$ ) range		Breakpoint <sup>a</sup> ( $\mu\text{g/ml}$ )	
	Vitek 2 System	Kirby-Bauer	Susceptible	Resistant
Ampicillin	0.5-32	0.015–32	$\leq 8$	$\geq 16$
Ampicillin-sulbactam	2-64	0.015–32	$\leq 8$	$\geq 16$
Benzylpenicillin	0.125-64	0.25 - 16	$\leq 8$	$\geq 16$
Cefuroxime	4-8	0.015–16	$\leq 4$	$\geq 8$
Ciprofloxacin	1-4	0.12 - 4	$\leq 1$	$\geq 4$
Clindamycin	0.5-2	0.015–32	$\leq 0.5$	$\geq 4$
Erythromycin	0.25-2	0.015–32	$\leq 0.5$	$\geq 8$
Gentamicin, high level	150	500	$\leq 500$	$> 500$
Kanamycin, high level	200	128 - 1024	$\leq 512$	$>1024$
Streptomycin, high level	200	2000	$\leq 1000$	$\geq 1000$
Imipenem	8-32	0.015–16	$\leq 2$	$\geq 8$
Levofloxacin	0.25-8	0.015–32	$\leq 2$	$\geq 8$
Nitrofurantoin	16-64	2 - 64	$\leq 32$	$\geq 128$
Norfloxacin	0.5-4	0.03–16	$\leq 2$	$\geq 16$
Ofloxacin	0.5-4	0.03–64	$\leq 2$	$\geq 4$
Quinupristin-Dalfopristin	0.25-2	0.5 - 32	$\leq 1$	$\geq 4$
Teicoplanin	1-16	0.015–16	$\leq 8$	$\geq 32$
Tetracycline	0.5-2	0.03–16	$\leq 4$	$\geq 16$
Trimethoprim-sulfamethoxazole	160-640	20-40	$\leq 2/38$	$\geq 4/76$
Vancomycin	2-6	0.015–16	$\leq 4$	$> 32$

<sup>a</sup> means breakpoints of various antibiotics tested by Kirby-Bauer as described by Clinical & Laboratory Standards Institute (CLSI)

four *Staphylococcus aureus* and two isolates for each *Citrobacterfreundii*, *Klebsiella pneumoniae*, *Staphylococcus epidermidis*, *Enterobacter aerogenes* and *Escherichia coli*. Through these results, it is clear that the *E. faecalis* is the most common recovered bacteria in DFIs. After biochemical identification, 49 isolates of *E. faecalis*

were recognized biochemically by Vitek™ 2 compact system. Microflex LT results showed that a total of 52 (100%) *E. faecalis* isolates were correctly identified at the species level as 44.23% (23/52) strains were appropriately recognized with a log of 2.3-3.0, while 51.92% (27/52) were accurately well-known with a log 2.0-2.29. In contrast, only

two isolates (3.84%) were recognized at the genus level with a log score extending from 1.7 to 1.99. Six virulence genes (*asa1*, *GeIE*, *cylA*, *esp*, *hy1*, *VanA*, and *VanB*) were detected in all *E. faecalis* isolates.

**Antibiotic Susceptibility and MAR of *E. faecalis***

The minimum inhibitory concentrations (MICs) of 20 antibacterial drugs were detected for 52 *E. faecalis* isolates using Vitek 2 system cards via the Kirby-Bauer method. Table 2 and Fig. 1 show that the susceptibility of *E. faecalis* was 100% for ampicillin, ampicillin-sulbactam, benzylpenicillin, norfloxacin, and ofloxacin; 92% for nitrofurantoin, teicoplanin,

and vancomycin; 87% for imipenem; 81% for kanamycin (high concentrations) and tetracycline; 73% for levofloxacin; and 52% for streptomycin (high concentrations). The resistance was 100% for clindamycin and quinupristin-dalfopristin, 96% for cefuroxime, 90% for ciprofloxacin and erythromycin, 86% for trimethoprim-sulfamethoxazole, 54% for gentamicin (high concentration), 48% for streptomycin (high concentration), 27% for levofloxacin, and 19% for kanamycin (high concentration).

Table 3 illustrates the MAR index of 52 *E. faecalis* strains in diabetic foot infections. The mean value of MAR index of all *E. faecalis*

**Table 2.** Susceptibility of *E. faecalis* against antimicrobial agents using Vitek 2 cards with a reference of Kirby-Bauer method

Antimicrobial agent	VITEK 2 System				Kirby-Bauer method			
	Susceptibility		Resistant		Susceptibility		Resistant	
	No.	%	No.	%	No.	%	No.	%
Ampicillin	52	100	0	0	52	100	0	0
Ampicillin-sulbactam	52	100	0	0	52	100	0	0
Benzylpenicillin	52	100	0	0	52	100	0	0
Cefuroxime	0	0	50	96	0	0	52	100
Ciprofloxacin	5	10	47	90	5	10	47	90
Clindamycin	0	0	52	100	0	0	52	100
Erythromycin	5	10	47	90	4	8	48	92
Gentamicin, high level	24	46	28	54	24	46	28	54
Kanamycin, high level	42	81	10	19	40	77	12	23
Streptomycin, high level	27	52	26	48	27	52	26	48
Imipenem	45	87	7	13	46	88	6	12
Levofloxacin	38	73	14	27	38	73	14	27
Nitrofurantoin	50	96	2	4	52	100	0	0
Norfloxacin	52	100	0	0	52	100	0	0
Ofloxacin	52	100	0	0	52	100	0	0
Quinupristin-Dalfopristin	0	0	52	100	0	0	52	100
Teicoplanin	48	92	4	8	52	100	0	0
Tetracycline	42	81	10	19	40	77	12	23
Trimethoprim-sulfamethoxazole	7	14	45	86	6	11	46	89
Vancomycin	48	92	4	8	48	92	4	8

isolates was 0.373. All *E. faecalis* strains are resistant against numerous antibiotics (Fig. 2); the MAR index ranges from 0.20–0.60. Strain No.13 exhibited a high degree of resistance against 12 out of 20 antimicrobial agents (MAR index of 0.60) followed by strain Nos. 8 & 17, which were resistant to 11 of the 20 antibiotics (MAR index of 0.55). Strain Nos. 1, 2, 11, 14, 21, 40, & 41 had a MAR index of 0.50. Strain Nos. 33 & 43 had

the lowest resistant among all tested *E. faecalis* strains with a MAR index of 0.20. The percentage of *E. faecalis* strains with a MAR index > 0.2 was 50/52 (96.16%); the percentage of *E. faecalis* strains with a MAR index > 0.2 was 2/52 (3.84%). Consequently, *E. faecalis* is found to be extremely resistant to numerous antibiotics with high MAR indices.

**Table 3.** Multi antibiotic resistance (MAR) patterns distribution among 52 *E. faecalis* isolates

No. of strain	Antimicrobial resistance profile	MAR index
1	CEF, CIP, CLI, ERY, GEN/HL, IMI, LEV, QUI/D, TEI, TRI/S	0.50
2	CEF, CIP, CLI, ERY, GEN, IMI, LEV, QUI/D, TRI, VAN	0.50
3	CEF, CIP, CLI, ERY, GEN, QUI/D, TET, TRI, VAN	0.45
4	CEF, CIP, CLI, ERY, QUI/D, TET, TRI/S	0.35
5	CEF, CIP, CLI, ERY, GEN/HL, QUI/D, TRI/S	0.35
6	CEF, CIP, CLI, ERY, GEN/HL, LEV, QUI/D, TRI/S	0.40
7	CEF, CIP, CLI, ERY, GEN/HL, IMI, LEV, NIT, QUI/D, TRI/S	0.50
8	CEF, CIP, CLI, ERY, GEN/HL, IMI, LEV, NIT, QUI/D, TEI, TRI/S	0.55
9	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
10	CEF, CIP, CLI, ERY, GEN/HL, QUI/D, TRI/S	0.30
11	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, QUI/D, TRI/S	0.45
12	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, QUI/D, TET, TRI/S	0.50
13	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, IMI, LEV, QUI/D, TEI, TRI/S	0.60
14	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, LEV, QUI/D, TRI/S	0.50
15	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, QUI/D, TRI/S	0.45
16	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, QUI/D, TRI/S	0.45
17	CEF, CIP, CLI, KAN/HL, STR/HL, IMI, LEV, QUI/D, TEI, TET, TRI/S	0.55
18	CEF, CIP, CLI, ERY, STR/HL, QUI/D, VAN	0.35
19	CEF, CIP, CLI, ERY, STR/HL, QUI/D, VAN	0.35
20	CEF, CIP, CLI, ERY, KAN/HL, STR/HL, LEV, QUI/D, TRI/S	0.45
21	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, IMI, LEV, QUI/D	0.50
22	CEF, CIP, CLI, ERY, GEN/HL, KAN/HL, STR/HL, QUI/D, TRI/S	0.45
23	CEF, CIP, CLI, QUI/D, TRI/S	0.25
24	CEF, CIP, CLI, QUI/D, TRI/S	0.25
25	CEF, CIP, CLI, ERY, QUI/D, TET, TRI/S	0.35
26	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
27	CEF, CIP, CLI, ERY, STR/HL, QUI/D, TEI, TET	0.40
28	CEF, CIP, CLI, ERY, GEN/HL, STR/HL, QUI/D, TRI/S	0.40
29	CEF, CIP, CLI, ERY, GEN/HL, STR, QUI/D, TRI/S	0.40
30	CEF, CIP, CLI, ERY, GEN/HL, STR/HL, QUI/D, TRI/S	0.40
31	CEF, CIP, CLI, ERY, GEN/HL, STR/HL, QUI/D, TRI/S	0.40
32	CEF, CIP, CLI, ERY, GEN/HL, STR/HL, QUI/D, TRI/S	0.40
33	CEF, CLI, STR/HL, QUI/D	0.20
34	CEF, CIP, CLI, STR/HL, QUI/D	0.25
35	CEF, CIP, CLI, ERY, STR/HL, QUI/D, TET, TRI/S	0.25
36	CEF, CIP, CLI, ERY, STR/HL, TET, TRI/S	0.35
37	CEF, CLI, ERY, GEN/HL, STR/HL, TRI/S	0.30
38	CEF, CIP, CLI, ERY, GEN/HL, QUI/D, TRI/S	0.35
39	CEF, CIP, CLI, ERY, GEN/HL, QUI/D, TRI/S	0.35
40	CEF, CIP, CLI, ERY, GEN/HL, LEV, STR/HL, QUI/D, TET, TRI/S	0.50
41	CEF, CIP, CLI, ERY, GEN/HL, LEV, STR/HL, QUI/D, TET, TRI/S	0.50
42	CEF, CLI, ERY, QUI/D, TRI	0.25
43	CLI, ERY, QUI/D, TRI	0.20
44	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
45	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
46	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
47	CEF, CIP, CLI, ERY, QUI/D, TRI/S	0.30
48	CEF, CIP, CLI, ERY, QUI/D	0.25
49	CIP, CLI, ERY, GEN/HL, LEV, QUI/D	0.25
50	CEF, CLI, ERY, LEV, QUI/D, TRI/S	0.30
51	CEF, CIP, CLI, ERY, QUI/D	0.25
52	CEF, CIP, CLI, ERY, QUI/D	0.25

Ampicillin = AM; Ampicillin-sulbactam = AM/S; Benzylpenicillin = BP; Cefuroxime = CEF; Ciprofloxacin = CIP; Clindamycin = CLI; Erythromycin = ERY; Gentamicin high level = GEN/HL; Kanamycin, high level = KAN/HL; Streptomycin high level = STR/HL; Imipenem = IMI; Levofloxacin = LEV; Nitrofurantoin = NIT; Norfloxacin = NOR; Ofloxacin = OFL; Quinupristin-Dalfopristin = QUI/D; Teicoplanin = TEI; Tetracycline = TET; Trimethoprim-sulfamethoxazole = TRI/S; Vancomycin = VAN




Fig. 1. Susceptibility and resistance percentage (%) of *E. faecalis* against antimicrobial agents using Vitek 2 cards.



Fig. 2. Multi antibiotic resistance index (MAR index) patterns distribution among 52 *E. faecalis* isolates.

**DISCUSSION**

Most DFIs are polymicrobial and multidrug-resistant (MDR); the *Enterococcus* genus is an essential part of dangerous microbial milieu found in diabetic foot ulcers<sup>15,16</sup>. Previous work showed that the *Enterococcus* genus is one of the most important positive microorganisms isolated from diabetic foot patients. It significantly

contributes to the increasing rates of morbidity and mortality from this disease<sup>7</sup>. Recently, *Enterococcus* species have been shown to be significant nosocomial pathogens, and *E. faecalis* and *E. faecium* isolates are the most common and virulent nosocomial microorganisms in many parts of the world<sup>17</sup>.

The consequences of diabetic foot ulcers are very complex because the infection frequently becomes chronic and ultimately leads to increasing mortality rates. The misuse of antibiotics used in the treatment of DFIs can increase the ability of bacteria to establish strong resistance against various antibiotics; thus, they adversely affect health due to treatment failure<sup>7</sup>. This study screened 630 samples from DFIs for the presence *E. faecalis*, and 74 samples were positive: 52 *E. faecalis*, 8 *Acinetobacter baumannii*, 4 *Staphylococcus aureus*, 2 *Citrobacter freundii*, 2 *Klebsiella pneumoniae*, 2 *Staphylococcus epidermidis*, 2 *Enterobacter aerogenes*, and 2 *Escherichia coli*. These data confirm that *E. faecalis* is a keystone species in diabetic foot patients<sup>18</sup>.

The susceptibility data indicated that 100% of *E. faecalis* strains were highly sensitive to beta lactams (ampicillin & ampicillin-sulbactam), penicillin (benzylpenicillin), and fluoroquinolone (norfloxacin and ofloxacin) groups; 92% were sensitive to nitrofurantoin (nitrofurantoin) and glycopeptide (teicoplanin and vancomycin) groups; 87% were sensitive to the beta lactam (imipenem) group, 81% were sensitive to aminoglycosides (kanamycin, high concentration) and tetracycline, 73% were sensitive to fluoroquinolones (levofloxacin); and 52% were sensitive to aminoglycoside (high concentration streptomycin). This finding suggests that these antimicrobial agents can be used for empirical treatment of *E. faecalis* infections. Similar results were previously reported by Dupreet et al.<sup>19</sup> and Gopinath and Prakash<sup>20</sup> who stated that *E. faecalis* isolates were susceptible to ampicillin, tigecycline, and teicoplanin. In addition, Wu et al.<sup>21</sup> found that *E. faecalis* was most susceptible to ampicillin (100%) followed by vancomycin (96.6%), penicillin G (96.6%), and linezolid (86.2%).

One curious finding was that *E. faecalis* had multidrug resistance ( $e''4$  and  $d''12$ ). Based on our interpretations, the resistance rate of *E. faecalis* isolates against various antimicrobial drugs were 100% for clindamycin and quinupristin-dalfopristin, 96% for cefuroxime, 90% for ciprofloxacin and erythromycin, 86% for trimethoprim-sulfamethoxazole, 54% for gentamicin high level, 48% for streptomycin, high level, 27% for levofloxacin, 19% for kanamycin high level, and 13% for imipenem.

Similar results were obtained by Rams et al.<sup>22</sup> who tested the susceptibility of 47 subgingival *E. faecalis* clinical isolates against various antimicrobial drugs. They found that the isolates had *in vitro* resistance to clindamycin (100% resistant to 2 µg/ml), erythromycin (80.8%), and tetracycline (53.2%). Jia et al.<sup>23</sup> studied the resistance of *Enterococcus* species from a university hospital in China. They reported a higher frequency of tolerance to quinupristin/dalfopristin, minocycline, chloramphenicol, and tetracycline in *E. faecalis*. A Portuguese study by Semedo-Lemsaddek et al.<sup>7</sup> also reported multi-drug resistance against *Enterococcal* species isolated from DF patients. In Brazil, Komiyama et al.<sup>24</sup> found that an important proportion of the *E. faecalis* isolates recovered from oral biofilms were resistant to numerous antimicrobial drugs—especially to tetracycline, chloramphenicol, and erythromycin. Anvarinejad et al.<sup>25</sup> isolated 34 *Enterococcus* species from 86 diabetic patients and found that *E. faecalis* was the most commonly isolated *Enterococcus* species (50%). They also found that ciprofloxacin was the most resistant drug followed by gentamicin, imipenem, and vancomycin (20.6%) against isolates.

Our findings for carbapenem (imipenem) resistance among *E. faecalis* (13%) is incompatible with prior reports<sup>26</sup>, which showed that resistance rate of *E. faecalis* against other carbapenems (ertapenem) might be as high as 90%. Despite the alarming resistance to vancomycin reported *E. faecalis* isolates, we found low resistance to vancomycin (8%; 4/52). Although the CLSI stated that *Enterococcus* species may be sensitive *in vitro* to various antimicrobial drugs such as cephalosporins, aminoglycosides, clindamycin, and trimethoprim-sulfamethoxazole, these antibiotics are not active clinically and would not be described as vulnerable<sup>27</sup>.

Data on the causative microbes (bacteria) in diabetic foot patients and their sensitivity to antibiotics is critical for the proper treatment and monitoring of infection<sup>28</sup>. The MAR status seen in the majority of the *Enterococcus* genus remains extremely significant—particularly in chronic and severe *Enterococcal* infections in DFIs—because antibiotic resistance frequently leads to treatment failure. The existence of MAR in diabetic foot ulcer *Enterococci* is an urgent matter because it can likely

transfer that tolerance to other types of bacteria<sup>7</sup>. We found differences in the antimicrobial susceptibility and development of multi-drug resistance against *E. faecalis* as a function of location. This might be due to differences in drug prescription practices. Our results should be confirmed in a larger cohort because this is the first study to evaluate antimicrobial resistance profile against *E. faecalis* recovered from diabetic foot patients in Saudi Arabia.

## CONCLUSION

Antimicrobial susceptibility testing of *E. faecalis* can help optimize the use of antimicrobials. The high levels of antimicrobial resistance patterns seen here in *E. faecalis* are of serious alarm because it limits treatment possibilities and adversely affects the health of affected diabetic foot patients. Consequently, our findings should be considered in public health strategies and awareness programs.

## ACKNOWLEDGEMENTS

The authors gratefully acknowledge the King Abdulaziz City for Science and Technology, Saudi Arabia for funding this research (Project number 1-17-01-001-0054).

## CONFLICTS OF INTEREST

The author declares that there are no conflict of interest.

## REFERENCES

- Doria M, Rosado V, Pacheco LR, Hernandez M, Betriu A, Valls J, Franch-Nadal J, Fernandez, Mauricio D. Prevalence of Diabetic Foot Disease in Patients with Diabetes Mellitus under Renal Replacement Therapy in Lleida, Spain. *Biomed Res Int.*, 2016; **8**:1-8.
- Anvarinejad M, Pouladfar G, Japoni A, Bolandparvaz S, Satiary Z, Mardaneh J. Diabetic Foot Infections: Antibiotic Susceptibility Patterns and Determination of Antibiotic Cross-Resistance in Clinical Isolates of *Enterococcus Species* During 2012 - 2014 in Shiraz, Iran. *Arch Pediatr Infect Dis.*, 2017; **5**:e37680.
- Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R. A clinico microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. *Diabetes Care*, 2006; **29**:1727-1732.
- Khoharo HK, Ansari S, Qureshi F. Diabetic foot ulcers: Common isolated pathogens and in vitro antimicrobial activity. *Prof Med. J.*, 2009; **16**:53-60.
- Al Dawish MA, Robert AA, Braham R, Al Hayek AA, Al Saeed A, Ahmed RA, Al Sabaan FS. Diabetes Mellitus in Saudi Arabia: A Review of the Recent Literature. *Curr Diabetes Rev.*, 2016; **12**:359-368.
- Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? *Clin Microbiol Infect*, 2007; **13**:351-353.
- Semedo-Lemsaddek T, Mottola C, Alves-Barroco C, Cavaco-Silva P, Tavares L, Oliveira M. Characterization of multidrug-resistant diabetic foot ulcer *enterococci*. *Enferm Infecc Microbiol Clin.*, 2016; **34**:114-116.
- Fisher K, Phillips C. The ecology, epidemiology and virulence of *Enterococcus*. *Microbiology*, 2009; **155**:1749-1757.
- John VuCa, rvalho J. *Enterococcus*: review of its physiology, pathogenesis, diseases and the challenges it poses for clinical microbiology. *J Front Biol.*, 2001; **6**:357.
- Furlaneto-maia L, Rocha K, Siqueira V, Furlaneto M. Comparison between automated system and pcr-based method for identification and antimicrobial susceptibility profile of clinical *Enterococcus spp.* *Rev Inst Med Trop Sao Paulo.*, 2014; **56**:97-103.
- Mansilha A, Brandt D. Guidelines for treatment of patients with diabetes and infected ulcers. *J. Cardiovasc Surg (Torino)*, 2013; **54**:193-200.
- Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. *Int. J. Mol Sci.*, 2016; **17**:2120.
- CLSI, Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated from Animals, Approved Standards – (4th ed.). CLSI document VET01-A4, Wayne, PA, USA 2016.
- Khalili H, Soltani R, Negahban S, Abdollahi A, Gholami K. Reliability of Disk Diffusion Test Results for the Antimicrobial Susceptibility Testing of Nosocomial Gram-positive Microorganisms: Is E-test Method Better?. *Iran J Pharm Res Spring*, 2012; **11**:559-563.
- Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J. Global healthcare expenditure on diabetes for 2010 and 2030. *Diabetes Res Clin Pract.*, 2010; **87**:293-301.
- Mendes JJ, Marques-Costa A, Vilela C, Neves J, Candeias N, Cavaco-Silva P. Clinical and bacteriological survey of diabetic foot infections in Lisbon. *Diabetes Res Clin Pract.* 2012; **95**:153-61.
- Werner G, Coque TM, Franz CM, Grohmann E, Hegstad K, Jensen L, van Schaik W, Weaver K. Antibiotic resistant *enterococci*-Tales of a drug resistance gene trafficker. *Int J Med Microbiol.*, 2013; **303**:360-798.
- Higueta NIA, Huy MM. *Enterococcal* disease, epidemiology and implications for treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. *Enterococci: from commensals to leading causes of drug resistant infection*. Boston: Massachusetts Eye and Ear Infirmary 2014; 1-15.
- Dupre I, Zanetti S, Schito AM, Fadda G, Sechi LA. Incidence of virulence determinants in clinical *Enterococcus faecium* and *Enterococcus faecalis* isolates collected in Sardinia (Italy). *J Med Microbiol.*, 2003; **52**:491-498.
- Gopinath R, Prakash M. Antibacterial activity of three medicinal plants against clinically isolated multidrug resistant *Enterococcus faecalis*(MDRE). *Int J Curr*

- Microbiol App Sci.*, 2013; 2:6-14.
21. Wu M, Pan H, Leng W, Lei X, Chen L, and Liang Z. Distribution of Microbes and Drug Susceptibility in Patients with Diabetic Foot Infections in Southwest China. *Journal of Diabetes Research*, 2018; 1-9.
  22. Rams TE, Feik D, Mortensen JE, Degener JE, van Winkelhoff AJ. Antibiotic susceptibility of periodontal *Enterococcus faecalis*. *J. Periodontol*, 2013; 84:1026-33.
  23. Jia W, Gang Li, and Wang W. Prevalence and Antimicrobial Resistance of *Enterococcus* Species: A Hospital-Based Study in China. *Int J Environ Res Public Health*, 2014; 11:3424–3442.
  24. Komiyama EY, Lepesqueur LS, Yassuda CG, Samaranayake LP, Parahitiyawa NB, Balducci I, Koga CY. *Enterococcus* Species in the Oral Cavity: Prevalence, Virulence Factors and Antimicrobial Susceptibility. *Plos One*, 2016; 0163001.
  25. Anvarinejad M, Pouladfar G, Japoni A, Bolandparvaz S, Satiary Z, Abbasi P, Mardaneh J. Isolation and Antibiotic Susceptibility of the Microorganisms Isolated from Diabetic Foot Infections in Nemazee Hospital, Southern Iran. *Journal of Pathogens*, 2015; ID:328796.
  26. Citron DM, Goldstein EJ, Merriam CV, Lipsky BA, Abramson MA. Bacteriology of moderate-to-severe diabetic foot infections and in vitro activity of antimicrobial agents. *J Clin Microbiol.*, 2007; 45:2819-28.
  27. CLSI, Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; 20<sup>th</sup> informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, Pa 2011.
  28. Anvarinejad M, Japoni A, Razaatpour N, Mardaneh J, Abbasi P, Amin Shahidi M. Burn Patients Infected With Metallo-Beta-Lactamase Producing *Pseudomonas aeruginosa*: Multidrug-Resistant Strains. *Arch Trauma Res.*, 2014; 3:181-182.